Immatics Biotechnologies

Immatics Biotechnologies is a clinical-stage company dedicated to developing novel T cell receptor (TCR)-based immunotherapies for cancer. Founded in 2000, it has evolved from a platform-focused entity into a product-driven organization with a strategic focus on the PRAME antigen, expressed in over 50 cancer types. The company's integrated technology platforms enable the discovery of novel intracellular targets and the engineering of high-affinity TCRs against them, forming the basis for its pipeline of Adoptive Cell Therapies (ACT) and TCR Bispecifics. Its lead programs are advancing in clinical trials, positioning Immatics as a key player in the next generation of solid tumor oncology.

Integrated proprietary platforms: XPRESIDENT® for mass spectrometry-based discovery of HLA-presented cancer targets, and XCUBE® for the discovery and engineering of high-affinity T cell receptors (TCRs) against those targets.

Competes with Adaptimmune (MAGE-A4 TCR-T), Immunocore (approved TCR bispecific), and other biotechs in TCR space. Immatics' key differentiators are its proprietary target discovery platform, focused leadership on the high-prevalence PRAME antigen, and development of both cell therapy and bispecific modalities internally.